In an effort to support global initiatives to contain the spread of the new coronavirus (COVID-19), the Academy is presenting Spring 2020 events through online platforms and some of our previously scheduled events are being postponed to a later date. Please check our events listing for the latest information and contact our Customer Service team with any additional questions. For Academy programs and resources about COVID-19, click here.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.


Companion Diagnostics: From Biomarker Identification to Market Entry

Edited by Edited by Claudio Carini (Pfizer)
Companion Diagnostics: From Biomarker Identification to Market Entry

Published: June 2015

Volume 1346

Discusses the development of biomarker-based companion diagnostics to optimize diagnosis and treatment choices.
Learn More

The recent growth in complex biological data has enabled a major paradigm shift in health care away from one-size-fits-all approaches toward customized, patient-tailored therapies. Biomarker-based companion diagnostics (CDx), designed to identify responsive patient subpopulations or those likely to experience adverse drug effects, lie at the heart of this personalized, precision medicine movement. The conference \"Companion Diagnostics: From Biomarker Identification to Market Entry,\" held on April 28–29, 2014, at the New York Academy of Sciences, brought together international scientists and clinicians from academia, industry, and government—as well as healthcare policy makers, regulatory experts, insurance sector representatives, and other stakeholders—to discuss research, financial, and regulatory strategies that will facilitate CDx development and integration into clinical care. This Annals volume presents a collection of papers stemming from this conference and covering a range of topics, including functional proteomic biomarkers in cancer; development of maraviroc, a CCR5 antagonist for treatment of HIV, using a novel tropism assay; biomarkers for precision medicine in airways disease; mTOR activation as a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging; current opportunities and future prospects for personalized medicine in diabetes mellitus; innovation in metabolomics to improve personalized health care; some imminent but overlooked preanalytical and analytical challenges currently facing biomarkers and CDx; new indications for immunoassay-based CDx in oncology; and making personalized medicine more affordable.